Atomic in vivo nanogenerators such as actinium-225, thorium-227, and radium-223 are of increasing interest and importance in Targeted Alpha Therapy (TAT), in the treatment of patients with metastatic cancer diseases.

Targeted Alpha therapies have great potential in being integrated as one of the major treatment pillars in Oncology due to their astonishing treatment successes. Nevertheless, this modality has to overcome some obstacles and hurdles in order to be fully accepted. In this regard, different questions have to be carefully answered to achieve the best possible treatment option for each individual patient.